Abstract
Women with primary antiphospholipid syndrome (APS) can experience early recurrent miscarriage, placental insufficiency leading to intrauterine growth restriction (IUGR), late fetal death, pre‐eclampsia, placental abruption or premature delivery [1]. Because evidence‐based recommendations are flawed by lack of qualitative studies, we undertook a prospective study of the management of APS pregnancies in a dedicated clinic following the introduction of a standard protocol.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
